Czech National Centre for Evidence-Based Healthcare and Knowledge Translation (Cochrane Czech Republic, Czech CEBHC JBI Centre of Excellence, Masaryk University GRADE Centre), Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
3rd Internal Clinic of 1st Faculty of Medicine, Charles University, Czech Republic.
Int J Evid Based Healthc. 2019 Jun;17 Suppl 1:S48-S52. doi: 10.1097/XEB.0000000000000188.
The prevalence of diabetes is on the rise worldwide especially in developed countries. The aim of glucose management in all types of diabetes is to minimize chronic and acute complications associated with diabetes. All patients with type 1 diabetes mellitus (T1DM) require insulin. Main areas of technology advances in diabetes are continuous subcutaneous insulin infusion (CSII) and also continuous glucose monitoring systems for the management of patients with both types of diabetes. It is very important to analyse the epidemiological situation within each country before and during the clinical practice guidelines (CPGs) development and implementation. The analyses will allow us to monitor the effect of the CPG after its implementation.The aim of this short communication is to analyse the epidemiology of prevalence and incidence of diabetes mellitus and use of CSII to inform development of CPGs in the Czech Republic.The analysis is developed based on the data managed by Institute of Health Information and Statistics of the Czech Republic. We used the National Register of Reimbursed Health Services 2015-2017 as primary source, and the annual report type A (Ministry of Health) 1-01: for Diabetology (A MH 004) 2007-2017 was used as validation source. The presented data are related to the year 2016 because we were able to validate them based on the data from 2015 to 2017 for this cohort of patients.The number of patients with T1DM is increasing in the Czech Republic with no significant sex difference. Life expectancy is about 11 years lower in the T1DM population. The majority of the patients are in older age; however, these are not treated with CSII compared with the younger population. From 61 533 patients with T1DM, 81% were reported with acute and chronic complications in 2016. Only 5011 of these patients were reported as using CSII.
糖尿病的患病率在全球范围内呈上升趋势,尤其是在发达国家。所有 1 型糖尿病(T1DM)患者都需要胰岛素。糖尿病技术进步的主要领域是持续皮下胰岛素输注(CSII)和两种类型糖尿病患者管理的连续血糖监测系统。在制定和实施临床实践指南(CPGs)之前和期间,分析每个国家的流行病学情况非常重要。这些分析将使我们能够监测 CPG 实施后的效果。本简讯的目的是分析捷克共和国糖尿病患病率和发病率以及 CSII 使用情况的流行病学数据,以为 CPG 的制定提供信息。该分析基于捷克共和国卫生信息和统计局管理的数据开发。我们使用了 2015-2017 年国家报销卫生服务登记册作为主要来源,使用了 2007-2017 年年度报告类型 A(卫生部):糖尿病学(A MH 004)作为验证来源。所呈现的数据与 2016 年有关,因为我们能够根据 2015 年至 2017 年的数据对这一年龄组的患者进行验证。捷克共和国 T1DM 患者数量呈上升趋势,且性别差异无统计学意义。T1DM 人群的预期寿命约低 11 年。大多数患者年龄较大;然而,与年轻人群相比,这些患者并未接受 CSII 治疗。在 2016 年,61533 名 T1DM 患者中有 81%报告患有急性和慢性并发症。这些患者中仅有 5011 人报告使用 CSII。